Earnings Call · Q3 FY2022·2022-11-03

Q3 22EPS -100.00%*·Rev n/aQ2 22EPS +100.00%*·Rev n/aQ1 22EPS -20.69%·Rev n/aQ4 21EPS -21.21%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Mercedes Carrasco — Investor Relations

John Butler — Chief Executive Officer

David Spellman — Chief Financial Officer

−4.9%1d on move date−6.3% vs SPY3d−4.3%5d−3.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access